<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2024.1529950</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Advance in vascular anomalies of head and neck region: from bench to bedside</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Wang</surname> <given-names>Deming</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1800236/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Shen</surname> <given-names>Yuchen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1418926/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Xu</surname> <given-names>Shancai</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1663791/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Cai</surname> <given-names>Yu</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1980043/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Su</surname> <given-names>Lixin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c003"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/451982/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yakes</surname> <given-names>Wayne F.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1950723/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Fan</surname> <given-names>Xindong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/413304/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Vascular Anomaly Center, Department of Interventional Therapy, Shanghai Ninth People&#x00027;s Hospital, Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University</institution>, <addr-line>Harbin, Heilongjiang</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>The Yakes Vascular Malformation Center</institution>, <addr-line>Englewood, CO</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Diogo C. Haussen, Emory University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Xindong Fan <email>fanxindong&#x00040;aliyun.com</email></corresp>
<corresp id="c002">Wayne F. Yakes <email>wayne.yakes&#x00040;vascularmalformationcenter.com</email></corresp>
<corresp id="c003">Lixin Su <email>sulixin1975&#x00040;126.com</email></corresp>
<fn fn-type="equal" id="fn001"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1529950</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>11</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>12</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2024 Wang, Shen, Xu, Cai, Su, Yakes and Fan.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Wang, Shen, Xu, Cai, Su, Yakes and Fan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/61528/advance-in-vascular-anomalies-of-head-and-neck-region-from-bench-to-bedside" ext-link-type="uri">Editorial on the Research Topic <article-title>Advance in vascular anomalies of head and neck region: from bench to bedside</article-title></related-article>
<kwd-group>
<kwd>vascular anomalies</kwd>
<kwd>vascular tumor</kwd>
<kwd>vascular malformations</kwd>
<kwd>hemangioma</kwd>
<kwd>signaling/signaling pathways</kwd>
<kwd>treatment</kwd>
<kwd>translational research</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="6"/>
<page-count count="2"/>
<word-count count="1229"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Endovascular and Interventional Neurology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>We are pleased to present our Research Topic, which includes a total of 10 articles, discussing the state-of-art on vascular anomalies&#x00027; research.</p>
<p>Vascular anomalies are abnormalities or disorders of the vascular or lymphatic system, with a relatively higher prevalence in the head and neck region. According to the International Society for the Study of Vascular Anomalies (ISSVA), vascular anomalies are classified as either vascular tumors or malformations (<xref ref-type="bibr" rid="B1">1</xref>). Vascular tumors can be benign, locally aggressive, or malignant. Hemangioma is considered the most common type of benign vascular tumor, which is divided into infantile and congenital hemangioma; given the onset time, both are endowed with unique natural history. Other benign vascular tumors include tufted angioma, pyogenic granuloma, spindle-cell hemangioma, and intravenous lipomas, etc. When it comes to locally aggressive tumors, kaposiform hemangioendothelioma is prone to cause thrombocytopenia among affected infants and children, known as the Kasabach-Merritt phenomenon. Malignant tumors include angiosarcoma, epithelioid hemangioendothelioma, etc.</p>
<p>Regarding vascular tumors, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1447960">Fern&#x000E1;ndez-Alvarez et al.</ext-link> contributed valuable perspectives on the intravenous lipomas of the head and neck through an up-to-date literature review and summary.</p>
<p>Different from vascular tumors, vascular malformations mostly occur congenitally. In the light of the hemodynamics, vascular malformations can be sorted into low-flow (capillary malformation [CM], venous malformation [VM], and lymphatic malformation [LM]) and high-flow (arteriovenous fistula [AVF] and arteriovenous malformation [AVM]). According to ISSVA, vascular malformations are divided into the following types: simple, combined, vascular malformations of major named vessels, and vascular malformations associated with other anomalies.</p>
<p>For low-flow vascular malformations, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1417788">Azmoun et al.</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1431723">Zhang et al.</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1444896">Sun et al.</ext-link> have introduced novel sclerosants on VMs; <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1425395">Yuan and Wang</ext-link> contributed their experiences on the electrochemical therapy combined with injection of pingyangmycin treating VMs. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1450102">Yang et al.</ext-link> discussed the efficacy of surgical resection, sclerotherapy, and the combination of the two in treating LMs.</p>
<p>For high-flow vascular malformations, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1461341">Han et al.</ext-link> reported the efficacy and safety of embolization among scalp AVFs. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcvm.2024.1449480">Shen et al.</ext-link> demonstrated the promising prognosis of peripheral AVFs after coil-assisted ethanol embolization. Furthermore, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcvm.2024.1439839">Su et al.</ext-link> shed light on the presentation and countermeasures related to the cardiopulmonary collapse induced by ethanol embolization.</p>
<p>Thanks to the significant development of molecular genetics, our understanding of vascular malformations has gradually shifted from a macroscopic level to a microscopic one. Nowadays, gene mutations are the broadly acceptable etiology of vascular malformations and related syndromes, including somatic or germline types. For example, cutaneous or mucosal CM is considered the somatic mutation of <italic>GNAQ</italic>/<italic>GNA11</italic>; (<xref ref-type="bibr" rid="B2">2</xref>) common VM is caused by somatic mutation of <italic>TEK</italic>, whereas sporadic AVM results from <italic>MAP2K1</italic> somatic mutation (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Some genetic diseases, such as hereditary hemorrhagic telangiectasia or capillary malformation-arteriovenous malformation, happen due to the germline mutation of (<italic>ENG, ACVRL1</italic>, and <italic>SMAD4</italic>) and (<italic>RASA1</italic> and <italic>EPHB4</italic>), respectively (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Here, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2024.1493873">Solomon and Comi</ext-link> summarized the latest progress of Sturge-Weber syndrome, most commonly associated with a <italic>R183Q</italic> somatic mosaic mutation in the gene <italic>GNAQ</italic>, from a translational perspective.</p>
<p>Given the complex category and comprehensive system of vascular anomalies, scientists, and clinicians are still facing tremendous challenges in basic, clinical, and translational research. Nevertheless, the knowledge base related to vascular anomalies continues to accrue and further studies are needed to allow for the treatment optimization of these challenging conditions.</p>
</body>
<back>
<sec sec-type="author-contributions" id="s1">
<title>Author contributions</title>
<p>DW: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YS: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SX: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YC: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. LS: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. WY: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. XF: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s2">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>ISSVA</collab></person-group>. <source>ISSVA Classification of Vascular Anomalies</source> &#x000A9;<italic>2018 International Society for the Study of Vascular Anomalies</italic>. (<year>2018</year>). Available at: <ext-link ext-link-type="uri" xlink:href="https://www.issva.org/classification">issva.org/classification</ext-link> (accessed May, 2018).</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname> <given-names>JA</given-names></name> <name><surname>Huang</surname> <given-names>L</given-names></name> <name><surname>Vivero</surname> <given-names>MP</given-names></name> <name><surname>Kamitaki</surname> <given-names>N</given-names></name> <name><surname>Maclellan</surname> <given-names>RA</given-names></name> <name><surname>Mulliken</surname> <given-names>JB</given-names></name> <etal/></person-group>. <article-title>Endothelial cells from capillary malformations are enriched for somatic GNAQ mutations</article-title>. <source>Plast Reconstr Surg</source>. (<year>2016</year>) <volume>137</volume>:<fpage>77e</fpage>&#x02212;<lpage>82e</lpage>. <pub-id pub-id-type="doi">10.1097/PRS.0000000000001868</pub-id><pub-id pub-id-type="pmid">26368330</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vikkula</surname> <given-names>M</given-names></name> <name><surname>Boon</surname> <given-names>LM</given-names></name> <name><surname>Carraway KL</surname> <given-names>3rd</given-names></name> <name><surname>Calvert</surname> <given-names>JT</given-names></name> <name><surname>Diamonti</surname> <given-names>AJ</given-names></name> <name><surname>Goumnerov</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2</article-title>. <source>Cell</source>. (<year>1996</year>) <volume>87</volume>:<fpage>1181</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81814-0</pub-id><pub-id pub-id-type="pmid">8980225</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname> <given-names>JA</given-names></name> <name><surname>Konczyk</surname> <given-names>DJ</given-names></name> <name><surname>Smits</surname> <given-names>PJ</given-names></name> <name><surname>Kozakewich</surname> <given-names>HPW</given-names></name> <name><surname>Alomari</surname> <given-names>AI</given-names></name> <name><surname>Al-Ibraheemi</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations</article-title>. <source>Angiogenesis</source>. (<year>2019</year>) <volume>22</volume>:<fpage>547</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s10456-019-09678-w</pub-id><pub-id pub-id-type="pmid">31486960</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viteri-Noel</surname> <given-names>A</given-names></name> <name><surname>Gonzalez-Garcia</surname> <given-names>A</given-names></name> <name><surname>Patier</surname> <given-names>JL</given-names></name> <name><surname>Fabregate</surname> <given-names>M</given-names></name> <name><surname>Bara-Ledesma</surname> <given-names>N</given-names></name> <name><surname>Lopez-Rodriguez</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Hereditary hemorrhagic telangiectasia: genetics, pathophysiology, diagnosis, and management</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>:<fpage>175245</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11175245</pub-id><pub-id pub-id-type="pmid">36079173</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D</given-names></name> <name><surname>Van der Ent</surname> <given-names>MA</given-names></name> <name><surname>Lartey</surname> <given-names>NL</given-names></name> <name><surname>King</surname> <given-names>PD</given-names></name></person-group>. <article-title>EPHB4-RASA1-mediated negative regulation of Ras-MAPK signaling in the vasculature: implications for the treatment of EPHB4- and RASA1-related vascular anomalies in humans</article-title>. <source>Pharmaceuticals</source>. (<year>2023</year>) <volume>16</volume>:<fpage>20165</fpage>. <pub-id pub-id-type="doi">10.3390/ph16020165</pub-id><pub-id pub-id-type="pmid">37259315</pub-id></citation></ref>
</ref-list>
</back>
</article>